Q-Biologicals becomes part of Amatsigroup
French pharmaceutical conglomerate Amatsigroup has announced its acquisition of Q-Biologicals. Q-Biologicals was founded in 2011 as a VIB/UGent spin-off by several Innogenetics veterans and provides services in process development and biomanufacturing. Their GMP manufacturing processes of recombinant proteins, monoclonal antibodies and vaccines have successfully aided in more than 75 R&D projects.
With this consolidation, Amatsigroup continues its expansive strategy. Back in 2014 the French contract development manufacturing organization for human and veterinary pharmaceuticals also incorporated the Ghent-based SEPS Pharma into the Amatsigroup family. Now named AmatsiSEPS, the company focusses on enhanced bioavailability and oral formulation of drugs.
Former Q-Biologicals shareholders were VIB and the Flemish investment funds PMV and Fund+. The total sum of the acquisition was undisclosed.